This mechanism applies primarily to diabetic patients rather than those using semaglutide solely for weight management
Individual responses to different GLP-1 drugs vary
Abbreviations ASCVD: Atherosclerotic cardiovascular disease CHD: Coronary heart disease CI: Confidence interval CVD: Cardiovascular disease CVOT: Cardiovascular outcome trial DPP-4i: Dipeptidyl peptidase-4 inhibitor GLP-1: Glucagon-like peptide 1 GLP-1R: Glucagon-like peptide 1 receptor HbA1c: Glycated haemoglobin HR: Hazard ratio LDL: Low-density lipoprotein MACEs: Major cardiovascular events NO: Nitric oxide OR: Odds ratio PIONEER: Peptide Innovation for Early Diabetes Treatment ROS: Reactive oxygen species SC: Subcutaneous SNAC: Sodium N -[8-(2-hydroxybenzoyl)amino] caprylate TAGs: Triacylglycerols TGs: Triglycerides T2DM: Type 2 diabetes mellitus VLDL: Very-low-density lipoprotein References Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME
GLP-1 (Glucagon-Like Peptide-1) is secreted by intestinal L-cells in response to nutrient intake
Human GLP-1R, human DNGs, and His 6 -tagged human G 1 and G 2 were expressed in sf 9 insect cells (Expression systems) using baculovirus and then infected with three separate baculoviruses at a ratio of 5:2:2 for GLP-1R, DNGs and G 1 2
doi: 10.1016/j.eprac.2022.11.010 [PubMed] 37632497 Watson CJ, Edlow JA
